# Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease

> **NCT05671991** · PHASE4 · RECRUITING · sponsor: **Yale University** · enrollment: 30 (estimated)

## Conditions studied

- End Stage Renal Disease on Dialysis

## Interventions

- **DRUG:** Empagliflozin 25 mg vs Placebo
- **DRUG:** Empagliflozin 10 MG

## Key facts

- **NCT ID:** NCT05671991
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-06-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-03-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05671991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05671991, "Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT05671991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*